Sorrento Therapeutics und mRNA


Seite 1 von 7
Neuester Beitrag: 19.12.22 23:55
Eröffnet am:18.08.21 12:33von: Meikel 1 2 .Anzahl Beiträge:162
Neuester Beitrag:19.12.22 23:55von: Bullish_HopeLeser gesamt:39.507
Forum:Hot-Stocks Leser heute:24
Bewertet mit:
2


 
Seite: <
| 2 | 3 | 4 | 5 | 6 | 7 7  >  

1110 Postings, 1239 Tage Meikel 1 2 3Sorrento Therapeutics und mRNA

 
  
    #1
2
18.08.21 12:33
Sorrento Therapeutics, Inc. ist ein in der klinischen Phase befindliches und kommerzielles Biopharmaunternehmen. Das Unternehmen ist in zwei Segmenten tätig: Sorrento Therapeutics und Scilex. Das Segment Sorrento Therapeutics ist um seinen therapeutischen Bereich Immun-Onkologie herum organisiert. und nutzt seine G-MAB-Antikörperbibliothek und gezielte Verabreichungsmodalitäten, um die nächste Generation von Krebstherapeutika zu entwickeln.

Das Scilex-Segment ist um seine nicht-opioiden Schmerzbehandlungsoperationen herum organisiert.

Ich eröffne dieses neue Forum um aktiv Themen um die aktuelle Entwicklung
von Sorrento Theraputics Inc. (SRNE) zu diskutieren und Informationen auszutauschen

 

1110 Postings, 1239 Tage Meikel 1 2 3aktuelles Entwicklungsprogramm im Überblick

 
  
    #2
18.08.21 12:36
Sorrento Unveils Overview of Its MultiValent mRNA COVID-19 Vaccine Development Program
August 09, 2021 14:39 ET | Source: Sorrento Therapeutics, Inc.

https://www.globenewswire.com/news-release/2021/...pment-Program.html

The presentation can be viewed at:
https://investors.sorrentotherapeutics.com/...entations/presentations

 

1110 Postings, 1239 Tage Meikel 1 2 3Chart

 
  
    #3
18.08.21 12:41
noch auf neutral...

MACD Signal bricht aber von unten
leicht durch ...

es fehlen noch Infos...
über die aktuellen Entwicklungen..  
Angehängte Grafik:
srne_chart_18082021.png (verkleinert auf 33%) vergrößern
srne_chart_18082021.png

1110 Postings, 1239 Tage Meikel 1 2 3Notfallzulassung Mexico und Zusammenarbeit

 
  
    #5
18.08.21 12:56
wenn denn die ersten Umsätze kommen
wirds spannend..

finance.yahoo.com/news/...rXl23SQf9EQrs30BTEbnDqBzmbk4p_Gy5nV
 

1110 Postings, 1239 Tage Meikel 1 2 3Link

 
  
    #6
18.08.21 12:57


finance.yahoo.com/news/...rXl23SQf9EQrs30BTEbnDqBzmbk4p_Gy5nV
 

1110 Postings, 1239 Tage Meikel 1 2 3Nadelfeie Verabreichung

 
  
    #8
18.08.21 13:15
Nadelfreie Verabreichungstechnologie von Sorrento zur Maximierung
der Immunisierungseffizienz in den Lymphknoten

Sorrento Needle-Free Delivery Technology Designed to Maximize Immunization Efficiency

Lymph nodes are the primary organs for generating adaptive immune responses as dendritic cells activate T and B cells. Thus, delivering therapeutics directly
toward lymph nodes (versus most common method of delivery into muscle tissue or blood) presents an opportunity to potentially improve current vaccines.

Seite 12
https://investors.sorrentotherapeutics.com/...-4bf9-b935-7bb8c24fb39a  

1110 Postings, 1239 Tage Meikel 1 2 3Pipeline

 
  
    #9
18.08.21 13:25

1110 Postings, 1239 Tage Meikel 1 2 3modernste Produktionsstätten..

 
  
    #10
18.08.21 13:37
Judicial Manufacturing (Antibodies, Cell Therapies)

State-of-the-art cGMP antibody and cell therapy manufacturing facility located in San Diego, CA, initially designed to be a multi-product facility for the manufacture of bulk purified proteins and antibodies for use as therapeutics. The redesigned facility meets applicable cGMP requirements for manufacture of Investigational New Drugs, and now includes capabilities for cellular therapies.

https://sorrentotherapeutics.com/manufacturing/
 

1110 Postings, 1239 Tage Meikel 1 2 3Historie

 
  
    #11
18.08.21 13:42
Sorrento has had a long journey from a humble beginning to a diversified biopharma discovering and developing life changing medicine.

2009
Founded

2013
Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc.
Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp.

2014
Out-licensed PD-L1 for Greater China market to Lee’s Pharm

2016
Formed ImmuneOncia JV with Yuhan Pharmaceuticals
Acquired ZTlido® via majority stake in Scilex Pharmaceuticals
Acquired Bioserv Corporation for cGMP manufacturing operations
Formed Levena Suzhou Biopharma Co. LTD for Antibody Drug Conjugation (ADC) services

2017
Acquired Oncolytic Virus platform via the acquisition of Virttu Biologics Limited
Formed Celularity with Celgene and United Therapeutics

2018
Acquired Sofusa® Lymphatic Delivery System from Kimberly-Clark

2019
Acquired Semnur Pharmaceuticals
Formed Scilex Holding to consolidate the merger of Scilex Pharma and Semnur Pharma

2020
Exclusively licensed Abivertinib from ACEA Therapeutics for all indications worldwide, excluding China
Exclusively licensed HP-LAMP diagnostic platform from Columbia University for the detection of coronaviruses and influenza viruses
Acquired SmartPharm Therapeutics

2021
Acquired ACEA Therapeutics

https://sorrentotherapeutics.com/who-we-are/history/
   

1110 Postings, 1239 Tage Meikel 1 2 3....aus der Pipeline COVID19

 
  
    #12
18.08.21 13:51
COVITRACE (diagnostischer) Diagnosetest
Zulassungsantrag der FDA für den Notfall (EUA) erwartet

COVISTIX (diagnostischer) Antigentest
FDA-Antrag auf Zulassung zur Notfallverwendung (EUA) eingereicht

COVITRACK – Platin (diagnostischer) Antikörpertest der nächsten Generation
In der Endfertigung und klinischen Prüfung

https://sorrentotherapeutics.com/research/pipeline/





 

1110 Postings, 1239 Tage Meikel 1 2 3so das wars für heute...

 
  
    #13
18.08.21 13:52
Fazit:
Spekulativ früh dabei...
mal abwarten wenn die nächsten Meldungen kommen
 

1110 Postings, 1239 Tage Meikel 1 2 3einer geht noch - Phase 2 abgeschlossen

 
  
    #14
18.08.21 14:09
Study Design
https://clinicaltrials.gov/ct2/show/study/NCT04440007

Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate)
in Subjects Hospitalized With COVID-19 (SOC)

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) With Standard of Care Versus Standard of Care in Subjects Hospitalized With COVID-19
Actual Study Start Date : October 9, 2020
Estimated Primary Completion Date : May 5, 2021
Estimated Study Completion Date : July 2021  

1110 Postings, 1239 Tage Meikel 1 2 3Meldung Tochtergesellschaft

 
  
    #15
19.08.21 15:57
cilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary Announces Expansion of Ztlido® Managed Care Coverage for Additional 33 Million Lives
August 19, 2021 at 9:00 AM EDT
Download PDF

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Scilex Holding Company (SCILEX), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE), announced that, effective September 1, 2021, ZTlido® (lidocaine topical system) 1.8% has been added to multiple formularies, including two national PBMs (Pharmacy Benefit Managers), a national health plan and two regional health plans – thereby expanding coverage by up to 33 million lives. ZTlido (zee-tee-lie-doh) is indicated for relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain.

“With this expansion, up to 65% of lives nationally have covered or better access to ZTlido, with a reduction in need for prior authorization,” said Jaisim Shah, President and Chief Executive Officer of Scilex Holding Company. “ZTlido provides fast and significant PHN pain relief that can be sustained over time – without the trade-offs associated with other widely used options, notably impaired cognition and weight gain (seen with gabapentinoids), and analgesic tolerance and risk of addiction (seen with opioids). 1-4 In fact, ZTlido can be used in combination to optimize gabapentinoids by delivering additive, remarkable pain relief without adding to systemic adverse events – and the combination has the potential to reduce the use of opioids.”1,5,6,*

However, not all lidocaine patch products are created equal. ZTlido 1.8% uses proprietary ZTech advanced technology to provide 9x greater bioavailability versus 5% lidocaine patch and superior adhesion proven in head-to-head studies, and while showering, bathing or exercising.7-12 This ensures that pain relief is delivered for the full treatment duration, without interrupting a patient’s routine.

ZTlido was approved by the U.S. Food and Drug Administration (FDA) in 2018 for relief of pain associated with post-herpetic neuralgia (PHN) in adults. Side effects of ZTlido include application site reactions such as, irritation, erythema, and pruritus.  

1110 Postings, 1239 Tage Meikel 1 2 3Medikament für Schmerzen / Gürtelrose

 
  
    #17
19.08.21 16:03

1418 Postings, 3411 Tage oli25Pipeline

 
  
    #18
19.08.21 16:16
Ja, die Pipeline hats wirklich in sich.
Hier gibte es einige Katalysatoren für den Kurs, wenn alles so läuft wie geplant.
Viel Glück allen Investierten.  

2086 Postings, 2916 Tage Unicorn71geht scheinbar endlich los!

 
  
    #19
20.08.21 08:33
Hat das laaaaaange Warten ein Ende?  

1110 Postings, 1239 Tage Meikel 1 2 3am besten gefällt mir

 
  
    #20
1
20.08.21 09:24
die Aussage auf Seite 3

"Mehrere Produkte im Spätstadium der klinischen Entwicklung
für Schmerztherapie, Immunonkologie und COVID-19"  
Angehängte Grafik:
seite_3_praesentation.jpg (verkleinert auf 43%) vergrößern
seite_3_praesentation.jpg

1110 Postings, 1239 Tage Meikel 1 2 3Termine zum vormerken

 
  
    #21
1
20.08.21 10:42
11.11.21 Q3 2021 Ergebnisveröffentlichung (geplant)

  18.03.22§ Jahr 2021 Ergebnisveröffentlichung (geplant)

  16.05.22§ Q1 2022 Ergebnisveröffentlichung (geplant)

 

1110 Postings, 1239 Tage Meikel 1 2 3Studie Abivertinib Phase 2

 
  
    #22
20.08.21 10:48
Studie zur Wirksamkeit und Sicherheit von STI-5656
(Abivertinib-Maleat) bei Patienten, die mit COVID-19
ins Krankenhaus eingeliefert wurden

https://ichgcp.net/de/clinical-trials-registry/NCT04440007

 

1110 Postings, 1239 Tage Meikel 1 2 3aus der Pipeline; Phase 2 abgeschlossen...

 
  
    #23
1
20.08.21 10:53
siehe auch thread #14

ABIVERTINIB

Abivertinib is a novel small molecule tyrosine kinase inhibitor (TKI) that selectively targets both mutant forms of the epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK) to treat Non-Small Cell Lung Cancer.  

More than 600 patients have been treated with Abivertinib at different oral doses up to 300 mg bid in multiple trials through registration trial (NCT03856697) in patients with non-small cell lung cancer (NSCLC) and B cell malignancies (Phase 1) conducted in China.  Favorable safety, tolerability and efficacy in patients with NSCLC or relapsed/refractory B-cell malignancies were demonstrated in the studies.

Abivertinib is also being tested as a potential treatment for cytokine storm associated with COVID-19 and as a potential treatment for cytokine release syndrome associated with CAR-T.
 

1110 Postings, 1239 Tage Meikel 1 2 3Tierstudien erfolgreich...

 
  
    #24
1
20.08.21 11:20
Sorrento highlights potential of experimental COVID-19 vaccine with animal study
Aug. 19, 2021 5:06 PM ETSorrento Therapeutics, Inc. (SRNE)Dyadic International, Inc. (DYAI)By: Dulan Lokuwithana, SA News

https://seekingalpha.com/news/...eed_news_all&utm_medium=referral



 

1110 Postings, 1239 Tage Meikel 1 2 3Meldung dazu...

 
  
    #25
1
20.08.21 11:22
Sorrento Announces Its Lead Protein-Based COVID-19 Vaccine Candidate – DYAI-100 – Elicits Strong Neutralizing Immune Responses in Vaccinated Animals Against SARS-CoV-2 and Multiple Major Variants of Concern

August 19, 2021 16:21 ET | Source: Sorrento Therapeutics, Inc.


https://www.globenewswire.com/news-release/2021/...-Multiple-Maj.html  

Seite: <
| 2 | 3 | 4 | 5 | 6 | 7 7  >  
   Antwort einfügen - nach oben